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Asthma and chronic obstructive pulmonary disease (COPD)
are the two most prominent chronic inﬂammatory lung dis-
eases, and their prevalence is still increasing. Although both
diseases are associated with genetic and environmental fac-
tors, their precise etiologies are still unclear. Recent advances
inbiologyandmedicinehaveintroducednewtechnologiesto
study the genetics and function of resident cells of the lungs,
and the data demonstrate a much broader range of impact
than previously envisaged. The function of resident cells of
the lung may be crucial to fully understand the pathology
of asthma and COPD. Knowledge and understanding of
resident cells will lead to the development of improved
animal models, more successful therapies, novel tools to
characterize asthma, and COPD and provide better care to
patients. In our present special issue, several outstanding
research groups present their original research articles that
will stimulate the continuing eﬀorts to understand the
molecular pathology underlying asthma and COPD, the
development of strategies to treat these conditions, and the
evaluation of outcomes. Moreover, several important novel
insights on the role of resident cells in asthma and COPD are
being reviewed in this special issue.
Y. Matsumura reviews the proteinase activity of many
common allergens and shows their interaction with lung
epithelial cells; they induce disruption of the tight junc-
tions between epithelial cells, activate the protease-activated
receptor-2, and lead to the production of thymic stromal
lymphopoietin. Hence, allergen source-derived proteases are
apotentiallycriticalfactorinthedevelopmentofallergicsen-
sitization and appear to be strongly associated with height-
enedallergenicity.S.KolahianandR.Gosensdescribeanovel
role of the parasympathetic neurotransmitter acetylcholine
in the regulation of airway remodeling and inﬂammation
in respiratory disease. Recent data have indicateed that
nonneuronal cells, including smooth muscle cells, secrete
acetylcholine and express receptors for acetylcholine. S.
Kolahian and R. Gosens focus on the role of acetylcholine
in smooth muscle cell function and review data to show
that the activation of acetylcholine receptors in these cells
can lead to proliferation, production of growth factors,
inﬂammatory mediators, and deposition of extra-cellular
matrix proteins. Moreover, it can lead to increased smooth
muscle mass, contractility, mucus gland remodeling and
airwayinﬂammationinvivoinaguineapigmodelofasthma.
Similarly, tiotropium studies show that acetylcholine may
contribute to cigarette smoke-induced neutrophilic airway
inﬂammation in a murine model of COPD. In addition to
the new role of acetylcholine, N. Miglino et al. present data
on another novel target to reduce bronchial smooth muscle
remodeling in their original research article. They show that
calreticulin, which has been described as a negative regulator
of C/EBPα [1], is also able to reduce airway smooth muscle
(ASM) cell proliferation and may thus provide beneﬁcial
eﬀectsonairwayremodeling.Thispathwaywasinsensitiveto
corticosteroids,whichmayexplainwhyairwayremodelingin
asthma patients is refractory to corticosteroid therapy [2]. In2 Journal of Allergy
particular subpopulations of asthma patients do not respond
well to the current therapy available for asthma. To identify
more eﬀective treatments, it is of importance to unlock
the underlying mechanisms and understand the genetic
background. A. Faiz and K. Burgess review the history
of expression microarray technologies, that is, genome-
wide association studies (GWASs)/locus ﬁne mapping, gene
candidate approaches, and gene expression studies (gene-
expression microarrays, including the Gene-Chip), and
their contribution to increase our understanding of asthma
pathology. For instance, GWASs have been essential in the
discovery of many asthma-associated genes, including disin-
tegrin and metalloproteinase domain-containing protein 33
(ADAM33). In addition, the 3 expression arrays have shown
that treatment with IL-13 caused deregulation of a number
of asthma-related genes in diﬀerent cell types of the airway,
including smooth muscle cells and airway epithelium.
TheASMcellhasbeenrecognizedasacriticaleﬀectercell
in the pathophysiology of asthma for almost a century. The
interplay between the smooth muscle and the pathophysiol-
ogy of asthma is reviewed by A. Ozier and colleagues. Specif-
ically they discuss the mechanisms driving airway hyper-
responsiveness in asthma, such as mediator release, altered
excitation/contraction coupling, and the role of airway
smooth muscle in bronchial inﬂammation and remodeling.
T. Chiba et al. prove a compelling review on the role of the
arylhydrocarbon receptor (AhR), a nuclear receptor which
responds to dioxins and dioxin-like compounds in cigarette
smoke and environmental pollutants. In their review they
discuss the role of AhR in asthma and COPD, focusing
upon how AhR modulates the immunological responses
in allergic and inﬂammatory diseases such as bronchi-
tis, asthma, and chronic obstructive pulmonary disease
(COPD) and the crosstalk of AhR signaling with other
ligand-activated transcription factors such as peroxisome
proliferator-activated receptors (PPARs). In addition to the
role of mesenchymal cells in innate immunity, mesenchymal
cells also have the ability to direct and in-turn can be
inﬂuenced by the adaptive immune system. One novel
example of this interaction is the role of immunoglobulin
receptors found upon the surface of mesenchymal cells. In
this issue, N. Roth reviews the role of immunoglobulin
receptors upon mesenchymal cell function and importantly
addresses some of the basic questions in this ﬁeld: why do
tissue-forming cells express immunoglobulin receptors and
do tissue-forming cells process immunoglobulin receptor-
bound particles?
Several drugs are currently in use targeting the inﬂam-
matory component of the asthmatic disorder, including
steroids and beta-mimetics [3]. It is well-established that
rhinovirus (RV)-induced asthma exacerbations account for
highasthma-relatedhealthcostsandmorbidity[4].D.vanLy
and coworkers studied the molecular mechanism underlying
this pathology involving RV-induced nuclear factor kappa
B( N F - κB)-dependent inﬂammation. To establish the role
of NF-κB inhibitors in RV-induced IL-6 and IL-8 and RV
replication, they used pharmacological inhibitors of NF-κB,
and steroids and/or β2 agonists were used as comparison.
Their data suggest that targeting NF-κB alone is unlikely
to be an eﬀective treatment compared to current asthma
therapeutics. Q. Ge and coworkers examined the eﬀect of
combined corticosteroids and long acting beta2-agonists on
in vitro extracellular matrix protein production by TGF-
stimulated airway smooth muscle (ASM) cells present in
isolated bronchial rings of nonasthmatic individuals. They
conclude that current combination asthma therapies are
unable to prevent or reverse remodeling events that are
regulated by ASM cells. Current asthma therapies have also
been in the spotlight of J. C. Allen et al. who investigated
corticosteroid insensitivity in vitro and were the ﬁrst to
examine the eﬀect of dexamethasone on the mitogen PDGF-
BB-induced cyclin D1 upregulation in ASM cells from both
nonasthmatics and asthmatics. They showed that cyclin D1
mRNA and protein up-regulation in cells from asthmatic
patients cannot be totally inhibited. These results agree with
earlier evidence that corticosteroid-inhibited proliferation
occurs only in ASM cells from nonasthmatics [5]a n d
suggest that there are corticosteroid insensitive proliferative
pathways in asthmatics that need to be further investigated
towards new eﬃcacious antiremodeling strategies.
A. Soltani and coworkers have had substantial experience
in using Collagen IV antibody as a blood vessel marker
in bronchial biopsies [6]. Therefore, they compared the
utility of anti-Collagen IV and anti-Factor VIII antibodies as
markers for blood vessels in bronchial biopsies from COPD
versus normal subjects and investigated the diﬀerences in
the vessels’ proﬁles that they stained. They showed that anti-
Collagen IV antibody tends to stain more vessels in the Rbm
andbiggervesselsoverallinboththeRbmandLP,whileanti-
Factor VIII antibody stains relatively smaller vessels. A novel
ﬁnding of this study was the increased leakiness of the vessels
in the Rbm in current smokers with COPD which is ripe
for speculation and further study and could be factored into
the concepts of the pathogenesis of smoking-related airway
disease pathophysiology. The complex pathophysiology of
COPD and asthma can be clariﬁed by the use of recent
advances in CT imaging. G. Dournes et al. present a
thorough yet concise review of quantitative measurements
of airway wall and lung parenchyma in both COPD and
asthma by using CT. Quantiﬁcation of airway wall and
lung parenchyma has demonstrated strong correlations with
clinical, functional, and pathological features in humans or
animal models.
Taken together, this special issue provides a focused
overview and state-of-the-art science related to the role and
function of resident cells of the lung, and how they may be
involved in developing and maintaining asthma and COPD
pathologies.
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